Among the exciting data presented at ASH in December 2018 were updates from two trials which are anticipated to have an impact on how relapsed/refractory multiple myeloma (R/R MM) is treated in Canada. ASH 2018 also featured an additional abstract of interest on the impact of lines of therapy when treating newly diagnosed MM (ND MM). Updated subgroup analyses based on cytogenic risk for these trials were presented at the ASCO and EHA conferences in June 2019. This report provides a review of these clinical trials with additional context and perspectives provided by CARE™ Faculty member Dr. Peter Anglin (Stronach Regional Cancer Centre).
This supplemental report has been updated to reflect/include new data points from the ASCO and EHA conferences.